PPM1D and myelodysplastic syndrome: Similarly, gain-of-function mutations in PPM1D are present in approximately 20% of cases of therapy-related AML and MDS but are rare in primary (de novo) AML, consistent with prior chemotherapy exposure strongly augmenting the fitness advantage of PPM1D-mutant CH clones (9).